Newer antihypertensive agents

References

• The Working Group on Hypertension in the Elderly. Statement on hypertension in the elderly. JAMA 1986: 256(1): 70–4
   PubMed Web of Science ®Google Scholar
• Kannel WB Wolf PA, McGee DL, et al. Systolic blood pressure, arterial rigidity, and risk of stroke: the Framingham study. JAMA 1981: 245(12): 1225–9
   PubMed Web of Science ®Google Scholar
• The 1988 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1988: 148(5): 1023–38
   PubMedGoogle Scholar
• Veterans Administration Cooperative Study Group on Antihypertensive Agents. Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. I. Results of short-term titration with emphasis on racial differences in response. JAMA 1982: 248(16): 1996–2003
   Web of Science ®Google Scholar
• Buhler FR, Burkart F, Lutold BE, et al. Antihypertensive beta blocking action as related to renin and age: a pharmacologic tool to identify pathogenetic mechanisms in essential hypertension. Am J Cardiol 1975: 36(5): 653–69
   PubMed Web of Science ®Google Scholar
• Davies RO, Irvin JD, Kramsch DK, et al. Enalapril worldwide experience. Am J Med 1984: 77(2A): 23–35
   PubMed Web of Science ®Google Scholar
• Schulman SP, Weiss JL, Becker LC, et al. The effects of antihypertensive therapy on left ventricular mass in elderly patients. N Engl J Med 1990: 322(19): 1350–6
   PubMed Web of Science ®Google Scholar
• Vestal RE, Wood AJ, Shand DG. Reduced beta-adrenoceptor sensitivity in the elderly. Clin Pharmacol Ther 1979: 26(2): 181–6
   PubMed Web of Science ®Google Scholar
• Buhler FR. Antihypertensive treatment according to age, plasma renin and race. Drugs 1988: 35(5): 495–503
   PubMed Web of Science ®Google Scholar
• Buhler FR, Bolli P, Kiowski W, et al. Renin profiling to select antihypertensive baseline drugs: renin inhibitors for high-renin and calcium entry blockers for low-renin patients. Am J Med 1984: 77(2A): 36–42
   PubMed Web of Science ®Google Scholar
• Laragh JH. Concept of anti-renin system therapy: historic perspective. Am J Med 1984: 77(2A): 1–6
   PubMed Web of Science ®Google Scholar
• Rey AM, Gums JG. Administration of ACEI test sublingually. (Letter) DICP 1990: 24(11): 1116–7
   Google Scholar
• Messerli FH, Sundgaard-Riise K, Ventura HO, et al. Essential hypertension in the elderly: haemodynamics, intravascular volume, plasma renin activity, and circulating catecholamine levels. Lancet 1983: 2(8357): 983–6
   PubMed Web of Science ®Google Scholar
• Beresford R, Heel RC. Betaxolol: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension. Drugs 1986: 31(1): 6–28
   PubMed Web of Science ®Google Scholar
• Riddell JG, Shanks RG. Comparative effects of betaxolol, propranolol, and atenolol on isoprenaline-induced responses in man. (Abstr) Br J Clin Pharmacol 1985: 19(1): 138P
   Web of Science ®Google Scholar
• Giudicelli JF, Chauvin M, Thuillez C, et al. Beta-adrenoceptor blocking effects and pharmacokinetics of betaxolol (SL 75212) in man. Br J Clin Pharmacol 1980: 10(1): 41–9
   PubMed Web of Science ®Google Scholar
• Mroczek WJ, Burris JF, Hogan LB, et al. Comparison of the antihypertensive effects of betaxolol to atenolol. Am J Cardiol 1988: 61(10): 807–11
   PubMed Web of Science ®Google Scholar
• Davidov ME, Glazer N, Wollam G, et al. Comparison of betaxolol, a new beta 1-adrenergic antagonist, to propranolol in the treatment of mild to moderate hypertension. Am J Hypertens 1988: 1(3 Pt 3): 206S–210S
   PubMed Web of Science ®Google Scholar
• Burris JF, Davidov ME, Jenkins P, et al. Comparison of the antihypertensive effects of betaxolol and chlorthalidone as monotherapy and in combination. Arch Intern Med 1989: 149(11): 2437–41
   PubMedGoogle Scholar
• Djian J. Clinical evaluation of betaxolol (Kerlone) as a once-daily treatment for hypertension in 4685 patients. Br J Clin Pract 1985: 39(5): 188–91
   PubMedGoogle Scholar
• Frances Y, Luccioni R, Vague P, et al. Effects of betaxolol, propranolol, and acebutolol on the glycoregulation after oral glucose tolerance test in hypertensive patients. In: Morselli PL, Kilborn JR, Carvero I, et al, eds. Betaxolol and other ß1-adrenoceptor antagonists. New York: Raven Press, 1983: 213–20 (LERS monograph series, vol 1)
   Google Scholar
• Schlanz KD, Thomas RL. Penbutolol: a new beta-adrenergic blocking agent. DICP 1990: 24(4): 403–8
   PubMedGoogle Scholar
• Heel RC, Brogden RN, Speight TM, et al. Penbutolol: a preliminary review of its pharmacological properties and therapeutic efficacy in hypertension and angina pectoris. Drugs 1981: 22(1): 1–25
   PubMed Web of Science ®Google Scholar
• Frishman WH, Covey S. Penbutolol and carteolol: two new beta-adrenergic blockers with partial agonism. J Clin Pharmacol 1990: 30(5): 412–21
   PubMed Web of Science ®Google Scholar
• Schoenberger JA. Usefulness of penbutolol for systemic hypertension. Am J Cardiol 1989: 63(18): 1339–42
   PubMed Web of Science ®Google Scholar
• Kubik MM, Hanks GW. Single daily dose penbutolol in the treatment of hypertension: a double blind crossover comparison with propranolol. Eur J Clin Pharmacol 1980: 17(6): 409–13
   PubMed Web of Science ®Google Scholar
• Houtzagers JJ, Chadha DR. Once-daily penbutolol or atenolol can replace combination therapy in essential hypertension. J Int Med Res 1982: 10(1): 1–5
   PubMed Web of Science ®Google Scholar
• De Plaen JF, Vander Elst E, Van Ypersele de Strihou C. Penbutolol or hydrochlorothiazide once a day in hypertension: a controlled study with home measurements. Br J Clin Pharmacol 1981: 12(2): 215–21
   PubMed Web of Science ®Google Scholar
• Valimaki M, Maass L, Harno K, et al. Lipoprotein lipids and apoproteins during beta-blocker administration: comparison of penbutolol and atenolol. Eur J Clin Pharmacol 198630(1): 17–20
   PubMed Web of Science ®Google Scholar
• Hansson BG, Hokfelt B. Long-term treatment of moderate hypertension with penbutolol (Hoe 893d). III. Effects on glucose tolerance and insulin production. Eur J Clin Pharmacol 1976: 10(3/4): 157–62
   Web of Science ®Google Scholar
• Young RA, Brogden RN. Doxazosin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension. Drugs 1988: 35(5): 525–41
   PubMed Web of Science ®Google Scholar
• Cox DA, Leader JP, Milson JA, et al. The antihypertensive effects of doxazosin: a clinical overview. Br J Clin Pharmacol 1986: 21(Suppl 1): 83S–90S
   PubMedGoogle Scholar
• Torvik D, Madsbu HP Multicentre 12-week double-blind comparison of doxazosin, prazosin and placebo in patients with mild to moderate essential hypertension. Br J Clin Pharmacol 1986: 21 (Suppl 1): 69S–75S
   PubMed Web of Science ®Google Scholar
• Hayduk K, Schneider HT. Antihypertensive effects of doxazosin in systemic hypertension and comparison with terazosin. Am J Cardiol 1987: 59(14): 95G–98G
   PubMed Web of Science ®Google Scholar
• Trost BN, Weidmann P, Riesen W et al. Comparative effects of doxazosin and hydrochlorothiazide on serum lipids and blood pressure in essential hypertension. Am J Cardiol 1987: 59(14): 99G–104G
   PubMed Web of Science ®Google Scholar
• Verelan. Product monograph. Pearl River, NY: Lederle Laboratories, 1990
   Google Scholar
• McMahon FG. Management of essential hypertension: the once-a-day era. Mount Kisco, NY: Futura, 1990
   Google Scholar
• Rocco MB, Barry J, Campbell S, et al. Circadian variation of transient myocardial ischemia in patients with coronary artery disease. Circulation 1987: 75(2): 395–400
   PubMed Web of Science ®Google Scholar
• Zachariah PK, Sheps SG, Schirger A, et al. Verapamil and 24-hour ambulatory blood pressure monitoring in essential hypertension. Am J Cardiol 1986: 57(7): 74D–79D
   PubMed Web of Science ®Google Scholar
• Grauer K. Ambulatory blood pressure monitoring and hypertension. (Editorial) Am Fam Physician (in press)
   Google Scholar
• Swanson DR, Barclay BL, Wong PS, et al. Nifedipine gastrointestinal therapeutic system. Am J Med 1987: 83(6B): 3–9
   PubMedGoogle Scholar
• Vetrovec GW, Parker VE, Cole S, et al. Nifedipine gastrointestinal therapeutic system in stable angina pectoris: results of a multicenter open-label crossover comparison with standard nifedipine. Am J Med 1987: 83(6B): 24–9
   PubMedGoogle Scholar